This report includes coverage of immuno-oncology overview, trends, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment - major current and future players in the immuno-oncology field.
The global market value for bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies, cytokines, and oncolytic viruses increased from $10.4 billion in 2014 to $74 billion in 2024.
This growth trajectory is expected to continue, with the total market reaching $186 billion by 2031, driven mainly by checkpoint modulators, followed closely by T-cell engagers.
China offers the broadest therapeutic access with 74 approved agents available, significantly more than the 53 agents accessible in the US, while non-small cell lung cancer is the indication with the highest number of approved immuno-oncology treatments.
Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.
The global market value for bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies, cytokines, and oncolytic viruses increased from $10.4 billion in 2014 to $74 billion in 2024.
This growth trajectory is expected to continue, with the total market reaching $186 billion by 2031, driven mainly by checkpoint modulators, followed closely by T-cell engagers.
China offers the broadest therapeutic access with 74 approved agents available, significantly more than the 53 agents accessible in the US, while non-small cell lung cancer is the indication with the highest number of approved immuno-oncology treatments.
Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.
Key Highlights
- This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China).
- The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
- Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market.
- The base year of the sales forecast model is 2023, and the forecast period is 2023-2033.
Scope
This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan, and China) includes the following topics:
- Immuno-oncology (IO) overview
- Trends
- Classes of IO drugs - immune checkpoint modulators, bispecific T-cell engagers, cell therapy, cytokine therapeutics, cancer vaccines, and oncolytic viruses
- Leading marketed and pipeline products
- Market analysis
- Regulatory landscape and market access
- Opportunities, challenges, and unmet needs
- Commercial assessment - major current and future players in the IO field
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global immuno-oncology therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global immune-oncology therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1. Preface
3. Immuno-oncology Overview
4. Trends
5. IO Classification
6 Marketed Products
7 Pipeline Products
8. Market Analysis
9. Regulatory and Market Access
10. Opportunities, Challenges, and Unmet Needs
11. Companies
12. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Allogene Therapeutics
- Amgen
- AstraZeneca
- BioNTech
- BMS
- Candel Therapeutics
- CG Oncology
- CRISPR Therapeutics
- Daiichi-Sankyo
- Dendreon Pharmaceuticals
- Genmab
- Gilead Sciences
- Greenwich LifeSciences
- Iovance Therapeutics
- Johnson & Johnson
- Kite
- Legend Biotech
- Merck & Co.
- Novartis
- Oncolytics Biotech
- Regeneron
- Replimune
- Roche
- Sanofi
- Xilio Therapeutics
